Mitochondria-targeted research peptide for controlled cellular-pathway studies.
- Dose
- 50 mg
- Batch
- 268027
SS-31 (Elamipretide)
Elamipretide — D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide (SS-31, MTP-131, Bendavia) · D-Arg-Dmt-Lys-Phe-NH2
For research purposes only — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Mitochondria-targeted research peptide for controlled cellular-pathway studies.
Members get 10% off every order, on top of volume pricing — become a member with a free account.
Volume savings are applied automatically at checkout. Larger orders: support@alptide.at
- Lab
- Janoshik Analytical
- Purity
- 99.756%
- Methods
- HPLC · LC-MS
- Tested
- Oct 6, 2026
For laboratory research use only. Not for human consumption.
Technical specifications
- Type
- Peptide
- Scientific name
- Elamipretide — D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide (SS-31, MTP-131, Bendavia)
- Amino acids
- 4
- Sequence
- D-Arg-Dmt-Lys-Phe-NH2
- Molecular weight
- 639.8 g/mol (free base)
- Formula
- C32H49N9O5
- CAS
- 736992-21-5
- Origin
- Fully synthetic Szeto-Schiller aromatic-cationic tetrapeptide (Weill Cornell, 2004); not a natural gene product — it contains D-arginine and 2',6'-dimethyltyrosine (Dmt) with a C-terminal amide, so no standard one-letter code represents it faithfully.
- Lyophilized (powder)
- -20°C, desiccated and protected from light · stable long-term (24+ months); -80°C for extended archival storage
- Reconstituted
- 2-8°C · use within ~30 days; aliquot to avoid repeated freeze-thaw cycles
- Room temperature
- Tolerates short shipping excursions of a few days as a sealed lyophilized powder. Not suitable for prolonged ambient storage — the powder is hygroscopic and moisture uptake drives gradual hydrolysis, and the phenolic dimethyltyrosine residue is oxidation- and light-sensitive. Reconstituted solution should not be held at room temperature.
Peer-reviewed research
Published research and registered trials involving this compound. Provided for educational reference only — none of it is a claim about this product.
- Journal of Biological ChemistryCell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injuryZhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH2004DOI: 10.1074/jbc.M402999200PMID: 15178689
- British Journal of PharmacologyFirst-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergeticsSzeto HH2014DOI: 10.1111/bph.12461PMID: 24117165
- Journal of the American Society of NephrologyThe mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipinBirk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH2013DOI: 10.1681/ASN.2012121216PMID: 23813215
- Aging CellMitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged miceSiegel MP, Kruse SE, Percival JM, Goh J, White CC, Hopkins HC, Kavanagh TJ, Szeto HH, Rabinovitch PS, Marcinek DJ2013DOI: 10.1111/acel.12102PMID: 23692570
- Circulation: Heart FailureNovel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of ElamipretideDaubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, O'Connor C, Goldstein S, Udelson JE, Sabbah HN2017DOI: 10.1161/CIRCHEARTFAILURE.117.004389PMID: 29217757
- Journal of Cachexia, Sarcopenia and MuscleA randomized crossover trial of elamipretide in adults with primary mitochondrial myopathyKaraa A, Haas R, Goldstein A, Vockley J, Cohen BH2020DOI: 10.1002/jcsm.12559PMID: 32096613
- NeurologyEfficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical TrialKaraa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, Goldstein A, Gorman GS, Haas R, Hirano M, Klopstock T, et al.2023DOI: 10.1212/WNL.0000000000207402PMID: 37268435
- Genetics in MedicineA phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolismReid Thompson W, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ2021DOI: 10.1038/s41436-020-01006-8PMID: 33077895
More in Metabolic
NAD+
500 mg / vial
Metabolic cofactor supplied for cellular energy and redox-pathway research.
Bacteriostatic Water
3 mL / vial
Laboratory diluent supplied for controlled reconstitution and handling workflows.
5-Amino-1MQ
50 mg / vial
Small-molecule research compound catalogued for metabolic-pathway studies.
AOD-9604
10 mg / vial
Growth-hormone-fragment research peptide catalogued for metabolic-pathway studies.